AcelRx Pharma (ACRX) Completes $10M Common, Warrants Private Placement
Get Alerts ACRX Hot Sheet
Join SI Premium – FREE
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012. Gross proceeds from the offering were approximately $10.0 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh
- Safe & Green (SGBX) Enters Agreement to Produce Four Modular Electrical Distribution Centers
- RTX (RTX) awarded $344 million contract to modernize electronics unit for missile development program
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!